Eubelius assists V-Bio Ventures with EuVECA application and third closing of V-Bio Fund 2

3 February 2022

Congratulations to V-Bio Ventures on increasing the capital of its second fund, V‑Bio Fund 2, to EUR 96 million. In order to internationalise this fundraising, V-Bio Fund 2 has obtained the official EuVECA (“European Venture Capital”) label, a marketing passport allowing it to market the fund cross-border within the EU. It is the first Belgian fund to obtain the EuVECA label.

We are proud to have provided both regulatory and corporate assistance to V-Bio Ventures in relation to the EuVECA application and the third closing. Eubelius had previously assisted V-Bio Ventures with the launch and earlier closings of the fund.

The Eubelius team consisted of Thomas Donnez, Michiel Stuyts and Odile Watté.